Cocrystal Pharma’s CC-42344 Shows Strong Antiviral Potency

Cocrystal Pharma ( (COCP) ) just unveiled an update.

Cocrystal Pharma announced on May 29, 2025, that its investigational drug candidate CC-42344 demonstrated strong antiviral potency against the 2024 highly pathogenic H5N1 avian influenza strain. The virology study showed that CC-42344 is approximately 1,000 times more potent than Tamiflu, a reference compound, and exhibits a favorable safety and tolerability profile. This development strengthens Cocrystal Pharma’s position in the influenza treatment market and supports further clinical evaluation of CC-42344, which could potentially address the multibillion-dollar influenza market.

The most recent analyst rating on (COCP) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Cocrystal Pharma stock, see the COCP Stock Forecast page.

Spark’s Take on COCP Stock

According to Spark, TipRanks’ AI Analyst, COCP is a Underperform.

Cocrystal Pharma faces significant financial challenges, with no revenue and ongoing operational losses severely affecting its stock score. The technical analysis indicates potential downward pressure, while the negative valuation metrics are concerning. However, recent corporate events provide some positive aspects, suggesting future growth potential. Overall, the company’s stock score reflects these mixed factors, indicating substantial risk with some long-term opportunities.

To see Spark’s full report on COCP stock, click here.

More about Cocrystal Pharma

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company focused on discovering and developing novel antiviral therapeutics targeting the replication process of influenza viruses, coronaviruses, noroviruses, and hepatitis C viruses. The company utilizes unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs.

Average Trading Volume: 16,833

Technical Sentiment Signal: Sell

Current Market Cap: $14.45M

See more data about COCP stock on TipRanks’ Stock Analysis page.